Advances in the treatment of unresectable locally advanced esophageal squamous carcinoma (Review)
- Authors:
- Lijun Wang
- Zichao Xu
- Mengqi Sun
- Hongwen He
- Zihuang Li
-
Affiliations: Department of Dongguan Hospital of Traditional Chinese Medicine, Dongguan, Guangdong 523000, P.R. China, Department of The Second Clinical Medical College of Jinan University, Department of Radiation Therapy, Shenzhen People's Hospital, Shenzhen, Guangdong 518000, P.R. China, Department of The Second Clinical Medical College of Jinan University, Department of Radiation Therapy, Shenzhen People's Hospital, Shenzhen, Guangdong 518000, P.R. China - Published online on: April 3, 2025 https://doi.org/10.3892/mco.2025.2845
- Article Number: 50
-
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Liang H, Fan JH and Qiao YL: Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China. Cancer Biol Med. 14:33–41. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Deboever N, Jones CM, Yamashita K, Ajani JA and Hofstetter WL: Advances in diagnosis and management of cancer of the esophagus. BMJ. 385(e074962)2024.PubMed/NCBI View Article : Google Scholar | |
|
Zeng H, Ran X, An L, Zheng R, Zhang S, Ji JS, Zhang Y, Chen W, Wei W and He J: HBCR Working Group. Disparities in stage at diagnosis for five common cancers in China: A multicentre, hospital-based, observational study. Lancet Public Health. 6:e877–e887. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Versteijne E, Van Laarhoven HW, Van Hooft JE, van Os RM, Geijsen ED, van Berge Henegouwen MI and Hulshof MC: Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: Locoregional recurrence pattern. Dis Esophagus. 28:453–459. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ochi M, Murakami Y, Nishibuchi I, Kubo K, Imano N, Takeuchi Y, Kimura T, Hamai Y, Emi M, Okada M and Nagata Y: Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma. J Radiat Res. 62:142–148. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Crosby T, Hurt CN, Falk S, Gollins S, Mukherjee S, Staffurth J, Ray R, Bashir N, Bridgewater JA, Geh JI, et al: Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial. Lancet Oncol. 14:627–637. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Yang Y, Mori SV, Li M, Hinkley M, Parikh AB, Collier KA, Miah A and Yin M: Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis. Cancer Med. 11:1669–1677. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Jiang W, Zhang B, Xu J, Xue L and Wang L: Current status and perspectives of esophageal cancer: A comprehensive review. Cancer Commun (Lond): Dec 26, 2024 (Epub ahead of print). | |
|
Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1623–1627. 1999.PubMed/NCBI View Article : Google Scholar | |
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Leeman JE, Li JG, Pei X, Venigalla P, Zumsteg ZS, Katsoulakis E, Lupovitch E, McBride SM, Tsai CJ, Boyle JO, et al: Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. JAMA Oncol. 3:1487–1494. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Sonnick MA, Oro F, Yan B, Desai A, Wu AJ, Shi W, Zhang Z, Gelblum DY, Paik PK, Yorke ED, et al: Identifying the optimal radiation dose in locally advanced non-small-cell lung cancer treated with definitive radiotherapy without concurrent chemotherapy. Clin Lung Cancer. 19:e131–e40. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Jouglar E, Isnardi V, Goulon D, Ségura-Ferlay C, Ayadi M, Dupuy C, Douillard JY, Mahé MA and Claude L: Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: Results from the Gating 2006 trial. Radiother Oncol. 126:291–299. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, et al: Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 28:2181–2190. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Suh YG, Lee IJ, Koom WS, Cha J, Lee JY, Kim SK and Lee CG: High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer. Jpn J Clin Oncol. 44:534–540. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Semrau R, Herzog SL, Vallböhmer D, Kocher M, Hölscher AH and Müller RP: Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer. Dis Esophagus. 25:545–554. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Ren X, Wang L, Han C and Ren L: Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma. Radiother Oncol. 129:293–299. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Chang CL, Tsai HC, Lin WC, Chang JH, Hsu HL, Chow JM, Yuan KS, Wu ATH and Wu SY: Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiother Oncol. 125:73–79. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Song T, Liang X, Fang M and Wu S: High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and pooled analysis. Expert Rev Anticancer Ther. 15:1157–1169. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hulshof MCCM, Geijsen ED, Rozema T, Oppedijk V, Buijsen J, Neelis KJ, Nuyttens JJME, van der Sangen MJC, Jeene PM, Reinders JG, et al: Randomized study on dose escalation in definitive chemoradiation for patients with locally advanced esophageal cancer (ARTDECO Study). J Clin Oncol. 39:2816–2824. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Xu Y, Dong B, Zhu W, Li J, Huang R, Sun Z, Yang X, Liu L, He H, Liao Z, et al: A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy Radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Clin Cancer Res. 28:1792–1799. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhang J, Li M, Zhang K, Zheng A, Li G, Chen S, Chen X, Li X, Sheng Y, Sun X, et al: Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for locally advanced esophageal squamous cell carcinoma: Results from a randomized, multicenter phase Ⅲ clinical trial. Inter J Rad Oncol Biol Phys. 114(S15)2022. | |
|
You J, Zhu S, Li J, Li J, Shen J, Zhao Y, Li X, Jia L, Li Q, Yang J, et al: High-Dose versus standard-dose intensity-modulated radiotherapy with concurrent paclitaxel plus carboplatin for patients with thoracic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, phase 3 superiority Trial. Int J Radiat Oncol Biol Phys. 115:1129–1137. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Wang J, Wu Y, Zhang W, Chen Y, Liu Q, Jing S, Zhang J, Wu F, Wang J and Qiao X: Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: A retrospective propensity study with 8-year survival outcomes. Radiat Oncol. 18(142)2023.PubMed/NCBI View Article : Google Scholar | |
|
Wang H, Song C, Zhao X, Deng W and Shen W: The role of involved field irradiation versus elective nodal irradiation in definitive radiotherapy or chemoradiotherapy for esophageal cancer-a systematic review and meta-analysis. Front Oncol. 12(1034656)2022.PubMed/NCBI View Article : Google Scholar | |
|
Li M, Zhang X, Zhao F, Luo Y, Kong L and Yu J: Involved-field radiotherapy for esophageal squamous cell carcinoma: Theory and practice. Radiat Oncol. 11(18)2016.PubMed/NCBI View Article : Google Scholar | |
|
Li Q, Zhu S, Li S and Deng W: Elective nodal irradiation provides a superior therapeutic modality for lymph node positivity esophageal squamous cell carcinoma patients receiving definitive radiotherapy versus involved-field irradiation. Medicine (Baltimore). 98(e14080)2019.PubMed/NCBI View Article : Google Scholar | |
|
Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, et al: Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res. 24:5058–5071. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Dai Y, Huang D, Zhao W and Wei J: A comparative study of elective nodal irradiation and involved field irradiation in elderly patients with advanced esophageal cancer. Front Oncol. 13(1323908)2023.PubMed/NCBI View Article : Google Scholar | |
|
Shinoda M, Ando N, Kato K, Ishikura S, Kato H, Tsubosa Y, Minashi K, Okabe H, Kimura Y, Kawano T, et al: Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 106:407–412. 2015.PubMed/NCBI View Article : Google Scholar | |
|
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366:2074–2084. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Chen Y, Ye J, Zhu Z, Zhao W, Zhou J, Wu C, Tang H, Fan M, Li L, Lin Q, et al: Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: A randomized, multicenter, phase III clinical trial. J Clin Oncol. 37:1695–1703. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Ai D, Ye J, Wei S, Li Y, Luo H, Cao J, Zhu Z, Zhao W, Lin Q, Yang H, et al: Comparison of 3 paclitaxel-based chemoradiotherapy regimens for patients with locally advanced esophageal squamous cell cancer: A Randomized clinical trial. JAMA Netw Open. 5(e220120)2022.PubMed/NCBI View Article : Google Scholar | |
|
Owens R, Cox C, Gomberg S, Pan S, Radhakrishna G, Parikh S, Goody R, Hingorani M, Prince S, Bird T, et al: Outcome of weekly carboplatin-paclitaxel-based definitive chemoradiation in oesophageal cancer in patients not considered to be suitable for platinum-fluoropyrimidine-based treatment: a multicentre, retrospective review. Clin Oncol (R Coll Radiol). 32:121–130. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Yada M, Yamamoto S, Honma Y, Hirano H, Okita N, Shoji H, Iwasa S, Takashima A, Nagahara A and Kato K: Retrospective analysis of definitive chemoradiotherapy with FOLFOX in patients with esophageal cancer intolerant to cisplatin. In Vivo. 38:761–766. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Satake H, Tahara M, Mochizuki S, Kato K, Hara H, Yokota T, Kiyota N, Kii T, Chin K, Zenda S, et al: A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacol. 78:91–99. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Sakai M, Sohda M, Saito H, Nakazawa N, Ubukata Y, Kuriyama K, Hara K, Sano A, Ogawa H, Yokobori T, et al: Concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) vs. cisplatin and 5-fluorouracil (CF-RT) for patients with unresectable locally advanced esophageal cancer in a real-world clinical setting. Anticancer Res. 41:2141–2145. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, Pawlak M, Dionne D, Xia J, Rozenblatt-Rosen O, et al: Checkpoint blockade immunotherapy induces dynamic changes in PD-1(-)CD8(+) tumor-infiltrating T cells. Immunity. 50:181–194.e6. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Yang YM, Hong P, Xu WW, He QY and Li B: Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 5(229)2020.PubMed/NCBI View Article : Google Scholar | |
|
Ko EC, Raben D and Formenti SC: The integration of radiotherapy with immunotherapy for the treatment of non-small cell lung cancer. Clin Cancer Res. 24:5792–5806. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, et al: Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res. 21:3727–3739. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Demaria S, Guha C, Schoenfeld J, Morris Z, Monjazeb A, Sikora A, Crittenden M, Shiao S, Khleif S, Gupta S, et al: Radiation dose and fraction in immunotherapy: One-size regimen does not fit all settings, so how does one choose? J Immunother Cancer. 9(e002038)2021.PubMed/NCBI View Article : Google Scholar | |
|
Salas-Benito D, Pérez-Gracia Jl, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, López-Picazo JM, Sanmamed MF and Melero I: Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 11:1353–1367. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Lian HM, Wu JL, Liufu WJ, Yu TT, Niu SQ, Bao Y and Peng F: Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: A propensity-score matched study. Cancer Immunol Immunother. 73(55)2024.PubMed/NCBI View Article : Google Scholar | |
|
Wang J, Cheng Y, Wu Y, Cao F, Liu Q and Gao G: 978P A prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer. Ann Oncol. 32(S838)2021. | |
|
Zhang W, Yan C, Zhang T, Chen X, Dong J, Zhao J, Han D, Wang J, Zhao G and Cao F: , et al: Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: A phase 1b study. Oncoimmunology. 10(1971418)2021.PubMed/NCBI View Article : Google Scholar | |
|
Park S, Oh D, Choi YL, Chi SA, Kim K, Ahn MJ and Sun JM: Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Cancer. 128:2148–2158. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, et al: Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): A single-arm, phase 2 trial. Lancet Oncol. 24:371–382. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Wang R, Ling Y, Chen B, Zhu Y, Hu Y, Liu M, Yang Y, Zhang L, Lv Y, Liu S, et al: Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: Insights from the EC-CRT-001 phase II trial. EClinicalMedicine,. 2024, 75: 102806, 2024. | |
|
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, et al: Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. Lancet Oncol. 15:305–314. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Gao LR, Wang X, Han W, Deng W, Li C, Wang X, Zhao Y, Ni W, Chang X, Zhou Z, et al: A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol. BMC Cancer. 20(901)2020.PubMed/NCBI View Article : Google Scholar | |
|
Ristau J, Thiel M, Katayama S, Schlampp I, Lang K, Häfner MF, Herfarth K, Debus J and Koerber SA: Simultaneous integrated boost concepts in definitive radiation therapy for esophageal cancer: Outcomes and toxicity. Radiat Oncol. 16(23)2021.PubMed/NCBI View Article : Google Scholar | |
|
Eze C, Schmidt-Hegemann NS, Sawicki LM, Walter F and Manapov F: Revisiting the role of dose escalation in esophageal cancer in the era of modern radiation delivery. J Thorac Dis. 12:1624–1627. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chang CL, Lin KC, Chen WM, Shia BC and Wu SY: Comparative effectiveness of intensity-modulated proton therapy versus intensity-modulated radiotherapy for patients with inoperable esophageal squamous cell carcinoma undergoing curative-intent concurrent chemoradiotherapy. J Thorac Oncol. 19:818–828. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Pöttgen C, Gkika E, Stahl M, Abu Jawad J, Gauler T, Kasper S, Trarbach T, Herrmann K, Lehmann N, Jöckel KH, et al: Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial. Radiat Oncol. 16(59)2021.PubMed/NCBI View Article : Google Scholar | |
|
Wang R, Liu S, Chen B, Li Q, Cheng X, Zhu Y, Zhang L, Hu Y, Liu M, Hu Y and Xi M: Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study. Br J Cancer. 131:709–717. 2024.PubMed/NCBI View Article : Google Scholar |
